- Home
- HIND vs AEON Comparison
HIND vs AEON Comparison
Compare HIND & AEON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$1.09
Company Overview
Basic Information| Metric | HIND | AEON |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.0M | 25.2M |
| IPO Year | 2016 | N/A |
Fundamental Metrics
Financial Performance| Metric | HIND | AEON |
|---|---|---|
| Price | $3.10 | $1.09 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.20 |
| AVG Volume (30 Days) | ★ 215.9K | 85.6K |
| Earning Date | N/A | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.75 | $0.38 |
| 52 Week High | $12.87 | $1.45 |
Technical Indicators
Market Signals| Indicator | HIND | AEON |
|---|---|---|
| Relative Strength Index (RSI) | 52.52 | 48.19 |
| Support Level | $1.75 | $0.67 |
| Resistance Level | $3.89 | $1.10 |
| Average True Range (ATR) | 0.27 | 0.12 |
| MACD | 0.10 | -0.00 |
| Stochastic Oscillator | 64.46 | 33.13 |
Price Performance
Historical Comparison HIND
AEON
About HIND Vyome Holdings Inc.
Vyome Holdings Inc is a reseach and development company. The Company operates in two segments, biotechnology and pharmaceutical products. The biotechnology segment comprises of operations around VT-1953, VT-1908, and VB-1953 programs that are in development, and the pharmaceutical segment comprises of antifungal products manufacturing and distribution.
About AEON AEON Biopharma Inc.
AEON Biopharma Inc is a clinical stage biopharmaceutical company focused on developing of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, with an initial focus on the neurosciences market.